BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Zhang J, Shen Q, Yin W, Huang H, Liu Y, Ni Q. High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett 2018;15:8789-95. [PMID: 29805618 DOI: 10.3892/ol.2018.8365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019;37:2592-2600. [PMID: 31356140 DOI: 10.1200/jco.19.01140] [Cited by in Crossref: 165] [Cited by in F6Publishing: 75] [Article Influence: 55.0] [Reference Citation Analysis]
2 Hurov K, Lahdenranta J, Upadhyaya P, Haines E, Cohen H, Repash E, Kanakia D, Ma J, Kristensson J, You F, Campbell C, Witty D, Kelly M, Blakemore S, Jeffrey P, McDonnell K, Brandish P, Keen N. BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism. J Immunother Cancer 2021;9:e002883. [PMID: 34725211 DOI: 10.1136/jitc-2021-002883] [Reference Citation Analysis]
3 Garcia-Sampedro A, Gaggia G, Ney A, Mahamed I, Acedo P. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. J Clin Med 2021;10:566. [PMID: 33546207 DOI: 10.3390/jcm10040566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lin X, Hu H, Pan Y, Gao S. The Prognostic Role of Expression of Nectin-4 in Esophageal Cancer. Med Sci Monit 2019;25:10089-94. [PMID: 31883369 DOI: 10.12659/MSM.918288] [Reference Citation Analysis]
5 Pang JS, Li ZK, Lin P, Wang XD, Chen G, Yan HB, Li SH. The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets. Oncol Rep 2019;41:2089-102. [PMID: 30816528 DOI: 10.3892/or.2019.7014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
6 Bekos C, Muqaku B, Dekan S, Horvat R, Polterauer S, Gerner C, Aust S, Pils D. NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer-An Integrative Multi-Omics Approach. Cancers (Basel) 2019;11:E698. [PMID: 31137558 DOI: 10.3390/cancers11050698] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Deng H, Shi H, Chen L, Zhou Y, Jiang J. Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. Cancer Cell Int 2019;19:106. [PMID: 31043861 DOI: 10.1186/s12935-019-0824-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
8 Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Charpak Amikam Y, Elnekave A, Tsukerman P, Kucan Brlic P, Lenac T, Seliger B, Jonjic S, Mandelboim O. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. J Immunother Cancer 2020;8:e000266. [PMID: 32503945 DOI: 10.1136/jitc-2019-000266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
9 Murata M, Ito T, Tanaka Y, Kaku-Ito Y, Furue M. NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target. Int J Mol Sci 2020;21:E5891. [PMID: 32824340 DOI: 10.3390/ijms21165891] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hanna KS. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma. Drugs 2020;80:1-7. [PMID: 31823332 DOI: 10.1007/s40265-019-01241-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
11 Halford Z, Anderson MK, Clark MD. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother 2021;55:772-82. [PMID: 32945172 DOI: 10.1177/1060028020960402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Lattanzi M, Rosenberg JE. The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Rev Anticancer Ther 2020;20:551-61. [PMID: 32552213 DOI: 10.1080/14737140.2020.1782201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Alt M, Stecca C, Tobin S, Jiang DM, Sridhar SS. Enfortumab Vedotin in urothelial cancer. Ther Adv Urol 2020;12:1756287220980192. [PMID: 33447264 DOI: 10.1177/1756287220980192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wong JL, Rosenberg JE. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Expert Opin Biol Ther 2021;21:863-73. [PMID: 34030536 DOI: 10.1080/14712598.2021.1929168] [Reference Citation Analysis]